Tyra Biosciences (NASDAQ:TYRA) Shares Down 5.6% After Analyst Downgrade

Key Points

• Tyra Biosciences shares fell 5.6% after HC Wainwright cut its price target from $45 to $30, although it maintained a Buy rating.
• Analyst sentiment remains broadly positive, with 11 Buy ratings, one Hold and one Sell, producing a consensus “Moderate Buy” rating and a $47.88 target price.
• Investor focus remains on mixed SURF302 results for dabogratinib in FGFR3-driven bladder cancer, with concerns that response rates fell short of expectations despite evidence of clinical activity.

Shares of Tyra Biosciences, Inc. (NASDAQ:TYRA - Get Free Report) dropped 5.6% on Friday after HC Wainwright lowered their price target on the stock from $45.00 to $30.00. HC Wainwright currently has a buy rating on the stock. Tyra Biosciences traded as low as $22.33 and last traded at $22.21. Approximately 913,818 shares changed hands during mid-day trading, an increase of 0% from the average daily volume of 912,001 shares. The stock had previously closed at $23.54.

Several other research firms have also recently commented on TYRA. Wolfe Research began coverage on Tyra Biosciences in a research report on Tuesday, May 19th. They issued a "peer perform" rating on the stock. Piper Sandler reiterated an "overweight" rating and issued a $56.00 target price on shares of Tyra Biosciences in a research report on Tuesday. Bank of America upped their target price on Tyra Biosciences from $37.00 to $42.00 and gave the stock a "buy" rating in a research report on Wednesday, June 10th. Jefferies Financial Group reaffirmed a "buy" rating and set a $42.00 target price on shares of Tyra Biosciences in a report on Wednesday, August 5th. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Tyra Biosciences in a research report on Friday, July 17th. Eleven equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $47.88.

Key Tyra Biosciences News

Here are the key news stories impacting Tyra Biosciences this week:

• Positive Sentiment: Wedbush maintained an “outperform” rating and set a $53 price target, implying substantial potential upside from recent trading levels. The firm’s stance suggests it views the selloff as excessive relative to Tyra’s longer-term prospects. Wedbush analyst rating report
• Positive Sentiment: Coverage of the SURF302 results indicated that dabogratinib demonstrated activity in FGFR3-driven bladder cancer, supporting continued development of Tyra’s lead program. The Pharma Letter SURF302 report
• Neutral Sentiment: HC Wainwright retained a “buy” rating but reduced its price target from $45 to $30, reflecting a more cautious outlook while still anticipating upside. HC Wainwright analyst rating report
• Neutral Sentiment: Reported short-interest data showed zero shares sold short, offering no meaningful indication of bearish positioning; the figure may reflect incomplete or unreliable data rather than a substantive trading signal.
• Negative Sentiment: Investors reacted negatively to initial SURF302 results because bladder-cancer response rates were viewed as falling short of expectations. Coverage described the data as disappointing, raising questions about dabogratinib’s competitive positioning and future commercial potential. BioSpace SURF302 coverage
• Negative Sentiment: Pomerantz LLP announced an investigation into potential claims on behalf of Tyra investors. The announcement does not establish wrongdoing, but it adds headline and legal risk at a time when sentiment is already weak. Pomerantz investor alert

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in TYRA. Hilton Head Capital Partners LLC acquired a new position in Tyra Biosciences in the 1st quarter worth approximately $30,000. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Tyra Biosciences in the fourth quarter worth $51,000. State of Wyoming purchased a new position in shares of Tyra Biosciences during the second quarter valued at $76,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in Tyra Biosciences by 14.5% during the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 13,182 shares of the company's stock valued at $126,000 after buying an additional 1,668 shares during the period. Finally, Russell Investments Group Ltd. lifted its stake in Tyra Biosciences by 27.7% in the 3rd quarter. Russell Investments Group Ltd. now owns 12,741 shares of the company's stock worth $178,000 after acquiring an additional 2,766 shares in the last quarter. 84.14% of the stock is owned by hedge funds and other institutional investors.

Tyra Biosciences Trading Down 6.3%

The stock has a market capitalization of $1.32 billion, a price-to-earnings ratio of -9.19 and a beta of 0.73. The stock has a 50-day simple moving average of $28.56 and a 200 day simple moving average of $31.91.

Tyra Biosciences (NASDAQ:TYRA - Get Free Report) last released its quarterly earnings data on Tuesday, August 4th. The company reported ($0.69) earnings per share for the quarter, missing the consensus estimate of ($0.65) by ($0.04). Sell-side analysts expect that Tyra Biosciences, Inc. will post -2.74 earnings per share for the current fiscal year.

About Tyra Biosciences

Tyra Biosciences NASDAQ: TYRA is a clinical-stage precision oncology company focused on the discovery and development of small-molecule therapies for genetically defined cancers. The company integrates bioinformatics, molecular biology and medicinal chemistry to identify oncogenic drivers and design targeted inhibitors. By leveraging large-scale genomic datasets and functional screening, Tyra Biosciences aims to advance therapies that address patient populations with high unmet medical need.

The company's pipeline includes multiple programs at various stages of development, each directed against distinct molecular vulnerabilities in cancer cells.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.